(IN BRIEF) GSK and Alfasigma have signed a licensing agreement granting Alfasigma worldwide exclusive rights to develop, manufacture and commercialise linerixibat, an investigational IBAT inhibitor for the treatment of cholestatic pruritus in patients with primary biliary cholangitis. The therapy is … Read the full press release
Posted in Business, Financial, Government, Healthcare, Industrial, Investment, Italy, Management, Marketing, Pharma & Biotech, Science, Technology, United Kingdom
Tagged Alfasigma, Alfasigma secures worldwide rights to linerixibat as GSK advances strategy in liver disease innovation, cholestatic pruritus therapy, drug development partnership, EU UK regulatory review, FDA approval process, Francesco Balestrieri, GLISTEN Phase III trial, global pharmaceutical collaboration, GSK, GSK partners with Alfasigma to advance linerixibat therapy for patients with primary biliary cholangitis, hepatology treatments, IBAT inhibitor, linerixibat, liver disease innovation, orphan drug designation, PBC treatment, pharmaceutical licensing agreement, primary biliary cholangitis, rare liver diseases, Tony Wood
(IN BRIEF) GSK’s marketing authorisation application for linerixibat, an investigational ileal bile acid transporter inhibitor, has been accepted for review by the European Medicines Agency. The submission is supported by GLISTEN Phase III trial data showing that linerixibat rapidly and … Read the full press release
Posted in Business, Healthcare, Pharma & Biotech, United Kingdom
Tagged alcohol-related liver disease, bile acid transporter, cholestatic pruritus, chronic hepatitis B, EASL Congress, EMA, European Medicines Agency, FDA, GLISTEN trial, GSK, IBAT inhibitor, itch-related sleep interference, Kaivan Khavandi, linerixibat, Marketing Authorisation Application, MASH, NCT04950127, orphan drug designation, PBC, Phase III, primary biliary cholangitis, UK regulatory review
EuropaWire (EW) is the first truly pan-European and leading press release distribution and newswire service for Europe and the European Union working towards consolidating Europe’s voice on the global newswire and media scene. The newswire service comes with advanced submission forms, flexible pricing and PR budgeting, granular targeting, nearly uncapped reach across countries, markets, verticals, industries, audiences, languages, etc., translation and localisation for greater local PR impact, in-depth distribution reporting, metrics and insights including measured PR reach, reads, engagements, impact, etc., no cap on words, images and multimedia to go along with your release, among others. Your press releases will be seen among the releases of Europe’s biggest and most prominent companies, brands and institutions. Here you can learn more about EuropaWire’s mission, achievements, services, etc.
HOW TO GET STARTED?